Jody A. Charnow

Patients with asymptomatic hyperuricemia who achieved serum uric acid levels of 6.0 mg/dL or less while on urate-lowering therapy had fewer gout flare episodes, a study found.

A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.

Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.

In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.

Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.

Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.

Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.

In a study comparing the effect of 9 oral nonsteroidal anti-inflammatory drugs on kidney function, ibuprofen conferred the lowest risk for incident eGFR less than 60 mL/min/1.73 m2 and an eGFR decline of 30% or greater.

Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.

New study is the first to characterize pegloticase use in the dialysis population.